

Contents lists available at ScienceDirect

Life Sciences

journal homepage: www.elsevier.com/locate/lifescie

Session 8: Pulmonary Hypertension

The evolving paradigm of pulmonary arterial hypertension and the evolving role of endothelin-1

David Langleben

*McGill University, Montreal, Canada**E-mail address: david.langleben@mcgill.ca*

Pulmonary arterial hypertension (PAH) remains a devastating illness, with an average survival that is still less than 5 years. Our understanding of PAH has evolved from considering it a disease of vasoconstriction, to recognizing that disordered cellular proliferation and resulting physical obstruction of the microvascular lumen are the principal causes of the increased pulmonary microvascular resistance. In parallel, insights gained from less frequent types of PAH, such as the heritable form of idiopathic PAH and PAH associated with Hereditary Hemorrhagic Telangiectasia, have highlighted the importance of disordered growth factor signalling in the origin and pathogenesis of the disease, particularly by members of the transforming growth factor β superfamily, including bone morphogenic proteins. Moreover, it has become clear that the endothelial cell is central to the disorder, in terms of abnormal cell signalling, mediators and proliferation. Emergence of apoptosis-resistant endothelial clones and change to a neoplastic phenotype are hallmarks of PAH. Endothelial-derived mediators normally help maintain vascular health. Abundant locally-produced prostacyclin and nitric oxide, and low levels of endothelin-1 normally preserve vascular patency. This balance is reversed in PAH, with low levels of prostacyclin and nitric oxide, and excess production of endothelin-1. Therapeutic blockade of endothelin-1 has resulted in clinical benefit for thousands of patients with PAH, who have had improvement in functional capacity and fewer clinical deteriorations. Each generation of endothelin antagonists improves on this track record. However, none of these agents is curative, and the potential reasons will be discussed. There is tremendous crosstalk between mediator systems in the vascular wall. With regard to endothelin-1, this is an area that requires further exploration, in order to understand the triggers for increased endothelin-1 levels and how to control them in PAH. Recent evidence suggests important interactions between the bone morphogenic protein and endothelin-1 systems, which deserve more study. The ultimate goal would be to suppress endothelin-1 synthesis and eliminate its contribution to the progression of this disorder.

doi:[10.1016/j.lfs.2013.12.113](https://doi.org/10.1016/j.lfs.2013.12.113)**Balloon pulmonary angioplasty as a treatment option for chronic thromboembolic pulmonary hypertension**

Hiromi Matsubara

*Department of Clinical Science, National Hospital Organization Okayama Medical Center, Japan**E-mail address: matsubara.hiromi@gmail.com*

Although pulmonary endarterectomy (PEA) can sufficiently decrease pulmonary arterial pressure (PAP) in patients with chronic thromboembolic pulmonary hypertension (CTEPH), not all patients can undergo PEA because of technical limitations. Several drugs such as endothelin receptor antagonist to treat pulmonary hypertension have been used to manage these patients, but sufficient decrease of PAP cannot be achieved. Balloon catheter would easily reach to surgically inaccessible lesions and therefore, we hypothesized that balloon pulmonary angioplasty (BPA) would be an effective treatment option for inoperable patients with CTEPH. We have treated 162 inoperable patients with CTEPH (WHO functional class III or IV despite full medical treatment, mean age 62 years old) with BPA. Mean PAP significantly decreased after BPA (from 44.9 to 24.0 mm Hg ($P < 0.001$)). Forty patients developed severe reperfusion pulmonary injury after BPA and 5 of them died during hospitalization. Additional 3 patients died during follow-up period and 3-year survival rate was 94.4%. Sixty-four out of 132 patients have been followed up for more than one year after BPA. Decrease of mean PAP was maintained (21.9 mm Hg). Thus, BPA would be an effective therapeutic option in these patients who have otherwise no proven treatment.

doi:[10.1016/j.lfs.2013.12.114](https://doi.org/10.1016/j.lfs.2013.12.114)**Adipose-derived regenerative cells therapy improves monocrotaline induced rat pulmonary arterial hypertension with suppressing endothelin-1 through an anti-inflammatory mechanism**

Masamichi Eguchi, Satoshi Ikeda, Daisuke Sato, Saburo Kusumoto, Yuji Koide, Hiroaki Kawano, Koji Maemura

*Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan**E-mail address: masa5555@nagasaki-u.ac.jp (M. Eguchi)*

Introduction pulmonary arterial hypertension (PAH) is characterized by functional and structural changes in the pulmonary vasculature, and despite the progress of pharmacotherapy, the prognosis of patients with advanced PAH remains poor. Adipose-derived regenerative cell (ADRC) therapy has recently emerged as a novel therapy for ailments of various organs by promoting cell regeneration at site of pathology. In this study, we investigated the efficacy of ADRCs therapy on PAH using monocrotaline (MCT)-induced PAH rat model, and explored underlying mechanisms.

Methods male Wistar rats were divided into the control, MCT, and MCT with ADRCs transfusion (M/A) group. Seven million ADRCs were transfused by intravenous injection at day 7. PAH was evaluated by measuring acceleration time (AT) and deceleration (Dct) of PA flow using echocardiography. At day 28, pathological changes in pulmonary vessels were assessed. The expression of genes associated with PAH was analyzed at day 14 by real time RT-PCR. Results Echocardiography showed that ADRCs therapy inhibited the development of PAH at day 28